Perceptions, Attributions, and Emotions Toward Endocrine Therapy in Young Women with Breast Cancer

Journal of Adolescent and Young Adult Oncology

Volumn 5, Issue 1, 2016, Pages 16-23

  Walker, Hayley E ^a   Rosenberg, Shoshana M ^a,b   Stanton, Annette L ^c   Petrie, Keith J ^d   Partridge, Ann H ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

breast cancer; psychosocial; survivorship

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; ARTICLE; ATTITUDE TO HEALTH; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; DISEASE ASSOCIATION; EMOTION; FEMALE; HEALTH SURVEY; HOT FLUSH; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; NIGHT SWEAT; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CHEMICALLY INDUCED; DRUG EFFECTS; LIBIDO; MIDDLE AGED; PROSPECTIVE STUDY; PSYCHOLOGY; RECURRENT DISEASE; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; SURVIVOR; SWEATING; YOUNG ADULT;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EMOTIONS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HOT FLASHES; HUMANS; LIBIDO; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; SOCIOECONOMIC FACTORS; SURVIVORS; SWEATING; YOUNG ADULT;

EID: 84977854680     PISSN: 21565333     EISSN: 2156535X     Source Type: Journal    
DOI: 10.1089/jayao.2015.0051     Document Type: Article

References (31)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472):1687-717.
2. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013; 381(9869):805-16.
3. Gray RG, Rea D, Handley K, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 2013;31(suppl; abstr 5).
4. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529-37.
5. McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008; 99(11):1763-8.
6. Makubate B, Donnan PT, Dewar JA, et al. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 2013;108(7):1515-24.
7. Huiart L, Ferdynus C, Giorgi R. A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Treat. 2013;138(1):325-8.
8. Murphy CC, Bartholomew LK, Carpentier MY, et al. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: A systematic review. Breast Cancer Res Treat. 2012;134(2):459-78.
9. Swain SM, Jeong J-H, Geyer CE, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053-65.
10. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2003; 21(4):602-6.
11. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(27):4120-8.
12. Ma AMT, Barone J, Wallis AE, et al. Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients. Am J Surg. 2008;196(4):500-4.
13. Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat. 2011;125(1): 191-200.
14. Land SR, Cronin WM, Wickerham DL, et al. Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial. Cancer Prev Res (Phila Pa). 2011; 4(9):1393-400.
15. Stanton AL, Petrie KJ, Partridge AH. Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Res Treat. 2014;145(2):525-34.
16. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6): 555-67.
17. Fink AK, Gurwitz J, Rakowski W, et al. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(16):3309-15.
18. Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns. 2005;59(1):97-102.
19. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97.
20. Gierisch JM, Earp JA, Brewer NT, Rimer BK. Longitudinal predictors of nonadherence to maintenance of mammography. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2010; 19(4):1103-11.
21. Williams RB, Barefoot JC, Califf RM, et al. Prognostic importance of social and economic resources among medically treated patients with angiographically documented coronary artery disease. JAMA. 1992;267(4):520-4.
22. Stanton AL, Bernaards CA, Ganz PA. The BCPT symptom scales: A measure of physical symptoms for women diagnosed with or at risk for breast cancer. J Natl Cancer Inst. 2005;97(6):448-56.
23. Crites SL, Fabrigar LR, Petty RE.Measuring the affective and cognitive properties of attitudes: conceptual and methodological issues. Pers Soc Psychol Bull. 1994;20(6):619-34.
24. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74.
25. Lash TL, Fox MP, Westrup JL, et al. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006;99(2):215-20.
26. Kahn KL, Schneider EC, Malin JL, et al. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care. 2007;45(5):431-9.
27. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(2):322-8.
28. Crandall C, Petersen L, Ganz PA, Greendale GA. Association of breast cancer and its therapy with menopauserelated symptoms. Menopause N Y N. 2004;11(5):519-30.
29. Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: A comparison of patient selfreport, pill counts, and microelectronic monitoring. J Clin Oncol Off J Am Soc Clin Oncol. 1993;11(6):1189-97.
30. Ziller V, Kalder M, Albert U-S, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol. 2009;20(3):431-6.
31. Huiart L, Bouhnik A-D, Rey D, et al. Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed? Eur J Cancer Oxf Engl 1990. 2012;48(13):1939-46.